Home / Pharmaceutical company intelligence
Atco Laboratories Limited logo
Pharmaceutical company intelligence

Atco Laboratories Limited

Pharmaceutical manufacturer · Karachi · Pakistan

Long-established Pakistan pharmaceutical manufacturer developing, formulating and marketing generic medicines from a cGMP-compliant Karachi facility.

Sourced corporate profile Corporate identity fields are source-tracked; portfolio, price and competitor intelligence remains independently calculated by MedInfoBase.
Official website ↗ Official contact ↗
ShareSend this page
Evidence & freshness

What is sourced, and how recent is it?

Public-source corporate details
Latest regulatory-source observation22 Sep 2026Newest linked source record observed by MedInfoBase
Latest portfolio source check22 Sep 2026Latest source-check date across this published portfolio
Latest effective price date27 Jul 2026Newest effective date among published current price records
Corporate profile evidence5 sourcesCorporate source details checked 16 Aug 2026

Regulatory-source portfolio data and company-supplied/corporate profile fields are tracked separately. Company claim/verification status is separate from source quality. An unclaimed company can still have a fully official-source-observed portfolio.

Regulatory & corporate identity

Company profile

Public-source corporate details
Company type
Pharmaceutical manufacturer
Address
B-18, S.I.T.E., Karachi-75700, Pakistan · 75700
Phone
+92 21 111 111 645
Official contact
Contact page ↗
Corporate source details checked
16 Aug 2026
Corporate profile completeness
100%
DRAP manufacturing licenceAs published by the DRAP Licensing Division. DRAP issues this list for stakeholder review and states it is not a reference for litigation, claims or citation.
Formulation 000188 Atco Laboratories Limited · Sindh
Source-linked licence identifiersShown as recorded in linked source rows; not a claim of current validity.
DML 000188 268 linked products · source seen 23 Sep 2026 View source ↗
DSL 025 10 linked products · source seen 23 Sep 2026 View source ↗
Corporate profile source ledger Logo Url source ↗ Contact Page Url source ↗ Logo Source Url source ↗
Location intelligence

Company location

Google Maps
Location recorded

A sourced company location is recorded. Use the map link below for directions.

Open in Google Maps ↗
Intelligence snapshot

Portfolio at a glance

Not sales data · published MedInfoBase database view
Rx278public portfolio records represented
REG183unique registrations represented
IDX278indexed MedInfoBase presentations
SRC0additional source-observed presentations
R+0registry-only registrations
VER0registry-verified exact registrations
PKR265current validated price records
G94generic molecules in indexed catalogue
DF15dosage-form groups
TA15therapeutic areas
How to read these counts

RegistrationA unique regulatory registration number. One registration may have more than one strength/form/pack presentation.

PresentationA distinct medicine presentation, such as a particular strength, dosage form and pack.

IndexedA canonical MedInfoBase presentation that passed MedInfoBase identity and publication controls.

Source observedAn additional presentation observed in an official DRAP source but not counted as an indexed MedInfoBase presentation.

Registry onlyAn exact registry-verified registration not otherwise represented by an indexed or source-observed presentation.

Registry verifiedAn exact registration match found in an official DRAP registry source. This is evidence status, not a commercial ranking.

Data coverage

How complete is this profile?

Current price coverage95%
public portfolio presentations with a validated current price
Official-source coverage100%
products linked back to a source record
Unit-price parse coverage100%
priced packs safely normalized per unit
Comparable-market coverage86%
products with at least one like-for-like comparator
Therapeutic classification100%
products assigned to a broad therapeutic area
Visual intelligence

Downloadable company intelligence charts

Copy or download any chart as a presentation-ready PNG. Every exported chart keeps MedInfoBase attribution and the source company-profile URL.

Shareable intelligence

Therapeutic Portfolio Mix

Shows where the company portfolio is concentrated across broad therapeutic areas.

Therapeutic Portfolio MixAtco Laboratories LimitedShare of current product presentations by broad therapeutic areaMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/atco-laboratories-limitedGenerated 23 Sep 2026Anti-infectives94 · 34%Cardiovascular51 · 18%Endocrine & metabolic33 · 12%Hematology & thrombosis29 · 10%Dermatology17 · 6%Pain & musculoskeletal12 · 4%CNS & mental health12 · 4%Other therapeutic areas30 · 11%Percentages are based on current product presentations in the MedInfoBase company portfolio.

Portfolio distribution, not sales or market-share data.

Shareable intelligence

Dosage Form Portfolio

Shows how the company portfolio is distributed across tablets, capsules, injections, liquids and other forms.

Dosage Form PortfolioAtco Laboratories LimitedDistribution of current product presentations by normalized dosage formMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/atco-laboratories-limitedGenerated 23 Sep 2026278presentationsTablet162 · 58%Injection25 · 9%Suspension23 · 8%Cream20 · 7%Capsule14 · 5%Solution10 · 4%Other forms24 · 9%Dosage-form wording is normalized for intelligence display; original source wording remains preserved in product records.

Counts are product presentations, not production or sales volumes.

Shareable intelligence

Equivalent Price Position

Shows whether safely comparable products are below, near or above the peer median unit price.

Equivalent Price PositionAtco Laboratories LimitedCurrent company products compared with like-for-like equivalent medicines using normalized unit pricesMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/atco-laboratories-limitedGenerated 23 Sep 2026240comparable productsBelow peer median89 · 37%Near peer median64 · 27%Above peer median87 · 36%Company median price position+0.0%Lowest-price equivalents39Method: same generic + stated strength + dosage form + compatible unit basis; pack prices normalized per unit.

This is price-position intelligence, not sales, demand or market-share data.

Shareable intelligence

Closest Portfolio Competitors

Highlights other manufacturers with the greatest generic overlap with this company portfolio.

Closest Portfolio CompetitorsAtco Laboratories LimitedCompanies with the largest number of shared generic medicines in the MedInfoBase databaseMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/atco-laboratories-limitedGenerated 23 Sep 2026Nabiqasim Industries (Pvt) Ltd.,50 shared53% overlapValor Pharmaceuticals44 shared47% overlapCCL Pharmaceuticals (Pvt.) Limited39 shared41% overlapTABROS PHARMA (PVT). LTD.39 shared41% overlapZafa Pharmaceutical Laboratories (P…38 shared40% overlapM/s. Genix Pharma (Pvt) Ltd.37 shared39% overlapPortfolio overlap measures shared generics only; it is not a measure of market share, affiliation or sales competition.

Competitor ranking is based on shared generics in MedInfoBase, not commercial sales performance.

Portfolio intelligence

Therapeutic areas

Broad portfolio view

High-level clinical areas represented by this company’s current MedInfoBase portfolio.

Anti-infectives94 products · 34%
Cardiovascular51 products · 18%
Endocrine & metabolic33 products · 12%
Hematology & thrombosis29 products · 10%
Dermatology17 products · 6%
Pain & musculoskeletal12 products · 4%
CNS & mental health12 products · 4%
Oncology & immunology11 products · 4%
Pharmacological detail

Drug classes

More specific view

More specific classes derived from the canonical generic and preserved curated classifications.

Antidiabetic medicines33 products · 12%
Antifungals18 products · 6%
Anticoagulants17 products · 6%
Calcium-channel blockers14 products · 5%
Antivirals13 products · 5%
Angiotensin receptor blockers13 products · 5%
Fluoroquinolone antibacterials11 products · 4%
Topical corticosteroids / anti-inflammatory dermatologics11 products · 4%
Formulation footprint

Dosage forms

Tablet162 products
Injection25 products
Suspension23 products
Cream20 products
Capsule14 products
Solution10 products
Ointment7 products
Drops4 products
Gel4 products
Lotion3 products
Sachet2 products
Inhalation1 products
How MedInfoBase classifies the portfolio

MedInfoBase uses a two-level taxonomy. Therapeutic area is a broad portfolio category, while drug class is the more specific pharmacological or clinical class. Existing curated classifications are preserved. Blank records are assigned conservatively from the canonical generic name and, when available, ATC information. Multi-use medicines may be placed in a cross-therapeutic category rather than forced into a single indication.

Portfolio leaders

Deepest brand families

Ranked by registered presentations · not sales
#1 Adrance-MEmpagliflozin + Metformin 19presentations 12.5 mg + 1000 mg, 12.5 mg + 500 mg, 12.5 mg + 850 mg, 5 mg + 1000 mg · Tablet #2 REVOBANRivaroxaban 11presentations 10 mg, 15 mg, 2.5 mg, 20 mg · Tablet #3 ADRANCEEmpagliflozin 10presentations 10 mg, 25 mg · Tablet #4 Tiocardis-AMTelmisartan + Amlodipine 9presentations 40 mg + 10 mg, 40 mg + 5 mg, 80 mg + 10 mg, 80 mg + 5 mg · Tablet #5 ASCARDAcetylsalicylic acid (Aspirin) 8presentations 100 mg, 150 mg, 300 mg, 75 mg · Tablet #6 BISOPROLOLBisoprolol fumarate 8presentations 10 mg, 2.5 mg, 5 mg · Tablet
Price intelligence

Unit-price positioning vs equivalent products

Same generic + strength + form + unit basis
Below market median8937% of comparable products
Near market median64within ±5% of median
Above market median8736% of comparable products
Lowest-price equivalents39ties included
Company median price position +0.0% relative to the median unit price of like-for-like equivalent products.
Most competitively positioned examplesProducts with at least 3 market comparators
SULFAZINE 1%Silver sulfadiazine · Cream · 500g PKR 1.55/g-72.0% vs market median Primox DS 800 mg + 160 mgSulfamethoxazole + Trimethoprim · Tablet · 100's PKR 2.91/tablet-68.5% vs market median Rumafen 200 mgIbuprofen · Tablet · 500's PKR 0.81/tablet-64.9% vs market median SULFAZINE 1 %Silver sulfadiazine · Cream · 250g PKR 1.55/g-59.3% vs market median Rumafen 200 mgIbuprofen · Tablet · 30's PKR 1.00/tablet-56.7% vs market median
How MedInfoBase calculates price position

Only current prices with safely interpretable pack quantities are used. A product is compared only with the same generic, same stated strength, same dosage form and a compatible unit basis such as tablet, capsule, mL or gram. These are database-derived price comparisons, not sales or market-share estimates.

Competitive landscape

Portfolio overlap

Companies sharing the largest number of generics with this portfolio. This measures product overlap, not commercial performance.

Nabiqasim Industries (Pvt) Ltd.,365 products · 118 generics 50shared generics Valor Pharmaceuticals219 products · 97 generics 44shared generics CCL Pharmaceuticals (Pvt.) Limited249 products · 99 generics 39shared generics TABROS PHARMA (PVT). LTD.179 products · 65 generics 39shared generics Zafa Pharmaceutical Laboratories (Pvt) Ltd.245 products · 97 generics 38shared generics M/s. Genix Pharma (Pvt) Ltd.297 products · 97 generics 37shared generics
Regulatory & price activity

Observed database signals

Indexed registration numbers183Distinct registrations among indexed, published, presentation-validated products only
Verified price observations279
Products with a verified price278
Products with multiple price observations1
Source records with multiple versions275
Latest portfolio source check22 Sep 2026
Latest effective price date27 Jul 2026
Latest source observation22 Sep 2026

These dates describe records observed by MedInfoBase. They should not be interpreted as product launch dates or sales activity.

Company medicine portfolio

Medicine portfolio

183 unique registration(s) · 278 indexed presentation(s)

This unified portfolio keeps three evidence lanes distinct: indexed MedInfoBase presentations, additional source-observed presentations, and registry-only registrations that are not otherwise represented. A registration number is not the same thing as a presentation, and source-observed rows are not counted as indexed. Source-only rows with a strength/form/pack contradiction remain visible as evidence but the conflicting field is held for normalization.

Reset
BrandGenericStrengthFormPackRegistrationSource-listed priceUnit pricePrice position
A-FANTRINE Artemether + Lumefantrine 20 mg + 120 mg Tablet 2 x 8's 047214 PKR 590.91 PKR 36.93/tablet 7% below median
A-FANTRINE Artemether + Lumefantrine 40 mg + 240 mg Tablet 8's 053368 PKR 556.65 PKR 69.58/tablet 9% above median
A-FANTRINE Artemether 80 mg Injection 1ml x 5's 073870 PKR 991.35 PKR 198.27/mL 12% above median
A-FANTRINE Artemether 40 mg Injection 1ml x 10's 073871 PKR 1,107.95 PKR 110.80/mL 12% below median
A-FANTRINE BD Artemether + Lumefantrine 80 mg + 480 mg Tablet 6's 058434 PKR 695.80 PKR 115.97/tablet 6% above median
A-FANTRINE BD Artemether + Lumefantrine 80 mg + 480 mg Tablet 4's 058434 PKR 406.24 PKR 101.56/tablet 7% below median
ADRANCE Empagliflozin 10 mg Tablet 7's 093079 PKR 632.48 PKR 90.35/tablet 9% above median
ADRANCE Empagliflozin 10 mg Tablet 10's 093079 PKR 902.98 PKR 90.30/tablet 9% above median
ADRANCE Empagliflozin 10 mg Tablet 14's 093079 PKR 1,264.95 PKR 90.35/tablet 9% above median
ADRANCE Empagliflozin 10 mg Tablet 28's 093079 PKR 2,479.29 PKR 88.55/tablet 7% above median
ADRANCE Empagliflozin 10 mg Tablet 30's 093079 PKR 2,656.39 PKR 88.55/tablet 7% above median
ADRANCE Empagliflozin 25 mg Tablet 7's 093080 PKR 757.03 PKR 108.15/tablet 8% above median
ADRANCE Empagliflozin 25 mg Tablet 10's 093080 PKR 1,082.02 PKR 108.20/tablet 9% above median
ADRANCE Empagliflozin 25 mg Tablet 14's 093080 PKR 1,514.04 PKR 108.15/tablet 8% above median
ADRANCE Empagliflozin 25 mg Tablet 28's 093080 PKR 2,967.76 PKR 105.99/tablet 6% above median
ADRANCE Empagliflozin 25 mg Tablet 30's 093080 PKR 3,179.88 PKR 106.00/tablet 6% above median
Adrance-M Empagliflozin + Metformin 12.5 mg + 850 mg Tablet 30s 095147 PKR 1,772.83 PKR 59.09/tablet 25% above median
Adrance-M Empagliflozin + Metformin 12.5 mg + 850 mg Tablet 10s 095147 PKR 602.34 PKR 60.23/tablet 27% above median
Adrance-M Empagliflozin + Metformin 12.5 mg + 850 mg Tablet 14s 095147 PKR 845.06 PKR 60.36/tablet 27% above median
Adrance-M Empagliflozin + Metformin 12.5 mg + 850 mg Tablet 28s 095147 PKR 1,655.96 PKR 59.14/tablet 25% above median
Adrance-M Empagliflozin + Metformin 12.5 mg + 850 mg Tablet 7s 095147 PKR 422.54 PKR 60.36/tablet 27% above median
Adrance-M Empagliflozin 5 mg Tablet 10’s 095148 PKR 508.84 PKR 50.88/tablet 15% above median
Adrance-M Empagliflozin + Metformin 5 mg + 850 mg Tablet 7’s 095148 PKR 356.00 PKR 50.86/tablet 9% above median
Adrance-M Empagliflozin + Metformin 5 mg + 850 mg Tablet 14’s 095148 PKR 713.82 PKR 50.99/tablet 9% above median
Adrance-M Empagliflozin + Metformin 5 mg + 850 mg Tablet 28’s 095148 PKR 1,398.84 PKR 49.96/tablet 6% above median
Adrance-M Empagliflozin + Metformin 12.5 mg + 1000 mg Tablet 28’s 095150 PKR 1,659.57 PKR 59.27/tablet Near median
Adrance-M Empagliflozin + Metformin 12.5 mg + 1000 mg Tablet 14’s 095150 PKR 846.86 PKR 60.49/tablet Near median
Adrance-M Empagliflozin + Metformin 5 mg + 1000 mg Tablet 28s 095151 PKR 1,402.44 PKR 50.09/tablet Near median
Adrance-M Empagliflozin + Metformin 5 mg + 1000 mg Tablet 14’s 095151 PKR 715.61 PKR 51.12/tablet Near median
Adrance-M Empagliflozin + Metformin 12.5 mg + 500 mg Tablet 28's 098695 PKR 1,630.80 PKR 58.24/tablet 14% above median
Adrance-M Empagliflozin + Metformin 12.5 mg + 500 mg Tablet 14's 098695 PKR 832.48 PKR 59.46/tablet 16% above median
Adrance-M Empagliflozin + Metformin 5 mg + 500 mg Tablet 7's 105253 PKR 341.13 PKR 48.73/tablet Near median
Adrance-M Empagliflozin + Metformin 5 mg + 500 mg Tablet 10's 105253 PKR 486.10 PKR 48.61/tablet Near median
Adrance-M Empagliflozin + Metformin 5 mg + 500 mg Tablet 14's 105253 PKR 680.83 PKR 48.63/tablet Near median
Adrance-M Empagliflozin + Metformin 5 mg + 500 mg Tablet 28's 105253 PKR 1,333.22 PKR 47.62/tablet Near median
Adrance-M Empagliflozin + Metformin 5 mg + 500 mg Tablet 30's 105253 PKR 1,429.87 PKR 47.66/tablet Near median
AMLOD Amlodipine 5 mg Tablet 20's 020398 PKR 262.04 PKR 13.10/tablet 21% above median
AMLOD-P Amlodipine 5 mg Tablet 10's 082105 PKR 407.26 PKR 40.73/tablet 276% above median
AMLOD-P Amlodipine + Perindopril tert-butylamine 5 mg + 8 mg Tablet 10's 082106 PKR 359.96 PKR 36.00/tablet No comparator
AMLOD-P Amlodipine + Perindopril tert-butylamine 10 mg + 8 mg Tablet 10's 082107 PKR 426.05 PKR 42.61/tablet No comparator
AMLOD-P Amlodipine + Perindopril 10 mg + 4 mg Tablet 10's 082108 PKR 453.20 PKR 45.32/tablet No comparator
ASCARD Acetylsalicylic acid (Aspirin) 75 mg Tablet 9 x 10's 016600 PKR 293.79 PKR 3.26/tablet 70% above median
ASCARD Acetylsalicylic acid (Aspirin) 75 mg Tablet 180's 016600 PKR 230.46 PKR 1.28/tablet 38% below median
ASCARD Acetylsalicylic acid (Aspirin) 75 mg Tablet 30's 016600 PKR 102.05 PKR 3.40/tablet 77% above median
ASCARD Acetylsalicylic acid (Aspirin) 75 mg Tablet 6 x 10's 016600 PKR 200.40 PKR 3.34/tablet 73% above median
ASCARD Acetylsalicylic acid (Aspirin) 300 mg Tablet 30's 016601 PKR 130.67 PKR 4.36/tablet 30% above median
ASCARD Acetylsalicylic acid (Aspirin) 150 mg Tablet 30's 022322 PKR 118.50 PKR 3.95/tablet 62% above median
ASCARD Acetylsalicylic acid (Aspirin) 150 mg Tablet 180's 022322 PKR 311.00 PKR 1.73/tablet 32% below median
ASCARD Acetylsalicylic acid (Aspirin) 100 mg Tablet 5x10's 028096 PKR 89.50 PKR 1.79/tablet 37% below median
Ascard Plus Clopidogrel + Aspirin 81 mg + 75 mg Tablet 10's 053363 PKR 256.16 PKR 25.62/tablet No comparator
MedInfoBase company-intelligence methodology

This page is generated from MedInfoBase medicine, generic, company, price and official-source records. Unverified third-party discovery records are retained internally for coverage auditing and are not published as company registrations. Portfolio leaders are ranked by presentation depth, not sales. Price-position metrics are calculated from current official-source prices normalized to compatible units and compared only against like-for-like products with the same generic, stated strength and dosage form.

Not currently included: sales volume, revenue by brand, market share, prescription volume or best-selling rankings. MedInfoBase will display those only when supported by a defensible licensed, public or company-verified source.

Cite this record

Manufacturer record
MedInfoBase. (2026). Atco Laboratories Limited — registered product portfolio in Pakistan [Data set]. MedInfoBase. Retrieved September 23, 2026, from https://medinfobase.com/company/atco-laboratories-limited/
Download .RIS Download .BIB EndNote, Zotero, Mendeley, RefWorks

Records change over time. Please cite the access date so readers can locate the version you used.